Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.65 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.42 |
| ▸ | CCKAR | P32238 | 3/20 | 0.42 |
| ▸ | CCKBR | P32239 | 3/20 | 0.42 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13908024 | 1.00 | GLP1R (0.65) | GLP1RNOD1FOLH1CCKARCCKBR | |
| SCHEMBL16153068 | 1.00 | GLP1R (0.65) | GLP1RNOD1FOLH1CCKARCCKBR | |
| SCHEMBL16182607 | 1.00 | GLP1R (0.65) | GLP1RNOD1FOLH1CCKARCCKBR | |
| SCHEMBL16182606 | 1.00 | GLP1R (0.65) | GLP1RNOD1FOLH1CCKARCCKBR | |
| SCHEMBL13184651 | 1.00 | GLP1R (0.65) | GLP1RNOD1FOLH1CCKARCCKBR | |
| SCHEMBL22402567 | 1.00 | GLP1R (0.65) | GLP1RNOD1FOLH1CCKARCCKBR | |
| SCHEMBL16426625 | 1.00 | GLP1R (0.65) | GLP1RNOD1FOLH1CCKARCCKBR | |
| SCHEMBL12686659 | 1.00 | GLP1R (0.65) | GLP1RNOD1FOLH1CCKARCCKBR | |
| SCHEMBL12686635 | 1.00 | GLP1R (0.65) | GLP1RNOD1FOLH1CCKARCCKBR | |
| SCHEMBL15358601 | 0.96 | GLP1R (0.65) | GLP1RNOD1FOLH1CCKARCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200407409-A1 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | CHEN JIANHE (CN) | 2020-12-31 | — | — | US | disclosed |
| US-20160271263-A1 | Acylated Glucagon Analogues | NOVO NORDISK AS (DK) | 2016-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160271263-A1 | Acylated Glucagon Analogues | GLP1R, GCG, IAPP | GLP1R 1/4885NOD1 2294/4885FOLH1 352/4885 |
| US-20200407409-A1 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | EGFR, LDLR, FFAR2 | GLP1R 39/4885NOD1 4794/4885FOLH1 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.